Skip to content

Use of phalatrikadi kwatha bhavit Haritaki churna in Diabetes patients

A CLINICAL STUDY OF STHOOLA PRAMEHI (DIABETES MELLITUS TYPE II) WITH TRIAL DRUG PHALTRIKADI KWATHA BHAVIT HARITAKI CHURNA - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083328
Enrollment
30
Registered
2025-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Government Akhandanand Ayurveda College BhadraAhmedabad Gujarat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Classical signs and symptoms of Prameha. Fasting plasma glucose 126- 200 mg per dl Post Prandial glucose level 200- 300 mg per dl. Only non-insulin-dependent Type II Diabetes Mellitus patients will be included. Both newly diagnosed patients on allopathic treatment will be included in this study. The dose of Modern Medicine will be adjusted and tapered during the period of trial as per need. Patients having BMI (Body Mass Index) greter than 25 and lesser than 35 will be taken for the study.

Exclusion criteria

Exclusion criteria: Patient age is below 18 years and above 65 years. Chronic Pancreatitis, Ketoacidosis, and Parkinson s disease. Patients with other metabolic and endocrinal disorders. BMI less than 25 and more than 35 will be excluded. Fasting plasma glucose level greater than 200 mg per dl & Postprandial glucose level greater than 300 mg per dl will be excluded Patients having any other malignancies or any other systemic or serious illness. Patients with diabetic wounds or ulcers Patients of Diabetes mellitus Type 1 (Juvenile Diabetes) Patients having acute & serious complications of Type 2 Diabetes Mellitus Patients with Coronary artery disease, Peripheral vascular disease & cerebrovascular disease Patients having a history of any major complications of Diabetes like Nephropathy, Retinopathy, Diabetic Foot, etc. Pregnant women Insulin-dependent patients. Otherwhere chronicles like STD, Tuberculosis, etc.

Design outcomes

Primary

MeasureTime frame
Improvement in laboratorial parameters as well as signs and symptoms of Sthoola Pramehi (Type II Diabetes Mellitus)Timepoint: 30 days

Secondary

MeasureTime frame
It is expected that the drug will break or eradicate the root cause of the disease leading to a permanent cure of Diabetes in Sthoola Pramehi by its Rasayana PropertiesTimepoint: 30 days

Countries

India

Contacts

Public ContactPrachi Darji

Government Akhandanand Ayurveda College and Hospital,,Ahmedabad Gujarat.

diptipandya73@yahoo.in9427794040

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026